60 related articles for article (PubMed ID: 3086313)
1. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
[TBL] [Abstract][Full Text] [Related]
2. Urokinase separation from cell culture broth of a human kidney cell line.
Bansal V; Roychoudhury PK; Kumar A
Int J Biol Sci; 2006 Nov; 3(1):64-70. PubMed ID: 17200693
[TBL] [Abstract][Full Text] [Related]
3. Vitronectin and Its Interaction with PAI-1 Suggests a Functional Link to Vascular Changes in AMD Pathobiology.
Biasella F; Strunz T; Kiel C; On Behalf Of The International Amd Genomics Consortium Iamdgc ; Weber BHF; Friedrich U
Cells; 2022 May; 11(11):. PubMed ID: 35681461
[TBL] [Abstract][Full Text] [Related]
4. A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.
Hanaoka S; Saijou S; Matsumura Y
Thromb Haemost; 2022 Jan; 122(1):57-66. PubMed ID: 33882608
[TBL] [Abstract][Full Text] [Related]
5. Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination.
Bhattacharya S; Ploplis VA; Castellino FJ
J Biomed Biotechnol; 2012; 2012():482096. PubMed ID: 23118509
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-ßs as modulators of pericellular proteolytic events.
Keski-Oja J; Lohi J; Laiho M
Cytotechnology; 1989 Dec; 2(4):317-32. PubMed ID: 22358872
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Makarova AM; Lebedeva TV; Nassar T; Higazi AA; Xue J; Carinato ME; Bdeir K; Cines DB; Stepanova V
J Biol Chem; 2011 Jul; 286(26):23044-53. PubMed ID: 21540184
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 regulates myoendothelial junction formation.
Heberlein KR; Straub AC; Best AK; Greyson MA; Looft-Wilson RC; Sharma PR; Meher A; Leitinger N; Isakson BE
Circ Res; 2010 Apr; 106(6):1092-102. PubMed ID: 20133900
[TBL] [Abstract][Full Text] [Related]
9. The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Allgayer H; Aguirre-Ghiso JA
APMIS; 2008; 116(7-8):602-14. PubMed ID: 18834405
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1.
Verheyden S; Sillen A; Gils A; Declerck PJ; Engelborghs Y
Biophys J; 2003 Jul; 85(1):501-10. PubMed ID: 12829505
[TBL] [Abstract][Full Text] [Related]
11. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance.
Vaughan DE
J Thromb Thrombolysis; 1995; 2(3):187-193. PubMed ID: 10608023
[TBL] [Abstract][Full Text] [Related]
14. Purification and cloning of a streptokinase from Streptococcus uberis.
Johnsen LB; Poulsen K; Kilian M; Petersen TE
Infect Immun; 1999 Mar; 67(3):1072-8. PubMed ID: 10024545
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Knoop A; Andreasen PA; Andersen JA; Hansen S; Laenkholm AV; Simonsen AC; Andersen J; Overgaard J; Rose C
Br J Cancer; 1998 Mar; 77(6):932-40. PubMed ID: 9528837
[TBL] [Abstract][Full Text] [Related]
17. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
Deng G; Curriden SA; Wang S; Rosenberg S; Loskutoff DJ
J Cell Biol; 1996 Sep; 134(6):1563-71. PubMed ID: 8830783
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.
Jeffers M; Rong S; Vande Woude GF
Mol Cell Biol; 1996 Mar; 16(3):1115-25. PubMed ID: 8622656
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.
Lyons-Giordano B; Loskutoff D; Chen CS; Lazarus G; Keeton M; Jensen PJ
Histochemistry; 1994 Feb; 101(2):105-12. PubMed ID: 8071082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
